Immunocore Holdings (IMCR) Other Non Operating Income (2023 - 2026)
Immunocore Holdings (IMCR) posted Other Non Operating Income of $3.8 million for Q1 2026, down 14.54% sequentially from $4.5 million in Q4 2025, and down 29.62% YoY from $5.5 million in Q1 2025.
Analysis
Immunocore Holdings (IMCR) Other Non Operating Income (2023 - 2026) Analysis & Trends
Immunocore Holdings has reported Other Non Operating Income for 4 years, with the latest figure at $3.8 million in Q1 2026.
- Quarterly Other Non Operating Income fell 29.62% year-over-year to $3.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $18.1 million (down 8.81% YoY) and the FY2025 annual result came in at $19.7 million, up 38.95% from the prior year.
- Other Non Operating Income eased to $3.8 million in Q1 2026 per IMCR's latest filing, from $4.5 million in the prior quarter.
- Over five years, Other Non Operating Income peaked at $11.2 million in Q3 2023 and troughed at -$12.5 million in Q4 2023.
- A 4-year average of $1.7 million and a median of $4.4 million in 2024 frame the typical range for Other Non Operating Income.
- The widest YoY moves for Other Non Operating Income: up 353.58% in 2025, down 43.52% in 2025.
- Over 4 years, Other Non Operating Income stood at -$12.5 million in 2023, then surged by 107.96% to $993000.0 in 2024, then jumped by 353.58% to $4.5 million in 2025, then declined by 14.54% to $3.8 million in 2026.
- According to Business Quant data, Other Non Operating Income over the past three periods registered $3.8 million, $4.5 million, and $5.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn |
| 10 | Immunocore Holdings | 1.85 Bn | 971.91 Mn | 114.84 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 3.07 Mn |
| Mar 31, 2026 | 3.85 Mn |
| Dec 31, 2025 | 4.50 Mn |
| Sep 30, 2025 | 5.06 Mn |
| Jun 30, 2025 | 4.69 Mn |
| Mar 31, 2025 | 5.47 Mn |
| Dec 31, 2024 | 993,000.00 |
| Sep 30, 2024 | 8.96 Mn |
| Jun 30, 2024 | 4.43 Mn |
| Mar 31, 2024 | -2.41 Mn |
| Dec 31, 2023 | -12.47 Mn |
| Sep 30, 2023 | 11.25 Mn |
| Jun 30, 2023 | -5.88 Mn |
| Mar 31, 2023 | -6.01 Mn |